Rhythm Pharmaceuticals, Inc. (NasdaqGM: RYTM)
Health Care · Biotechnology · US
$113.35
+1.71% today · +12.0% 1Y
Rhythm Pharmaceuticals, Inc. (NasdaqGM: RYTM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.80B and employs 414 people.
Over the last twelve months the share price has gained 12.0%, trading between 74.50 and 122.20.
Tweenvest scores Rhythm Pharmaceuticals, Inc. across four factors: quality 29/100, value 75/100. Its strongest factor is value.
RYTM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.80B
- Revenue (TTM)
- $239.92M
- P/E
- —
- EPS
- -3.12
- Dividend yield
- —
- Beta (5Y)
- 1.97
- 52-week high
- $122.20
- 52-week low
- $74.50
- Avg volume (3M)
- —
- Shares outstanding
- 68.85M
- Employees
- 414
- Next earnings
- —
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
- ISIN
- US76243J1051
- Founded
- 2008
- Listed since
- Oct 9, 2017
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.